Equities analysts expect MannKind Co. (NASDAQ:MNKD) to announce earnings of ($0.04) per share for the current quarter, Zacks reports. Three analysts have made estimates for MannKind’s earnings, with the highest EPS estimate coming in at ($0.04) and the lowest estimate coming in at ($0.05). MannKind reported earnings per share of ($0.03) in the same quarter last year, which would suggest a negative year-over-year growth rate of 33.3%. The business is expected to issue its next quarterly earnings report on Wednesday, May 5th.
On average, analysts expect that MannKind will report full-year earnings of ($0.17) per share for the current year, with EPS estimates ranging from ($0.20) to ($0.15). For the next year, analysts anticipate that the firm will post earnings of ($0.13) per share, with EPS estimates ranging from ($0.17) to ($0.08). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow MannKind.
MannKind (NASDAQ:MNKD) last announced its quarterly earnings data on Thursday, February 25th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.03). The firm had revenue of $18.44 million for the quarter, compared to analyst estimates of $16.13 million.
MNKD traded up $0.08 on Friday, hitting $4.16. 87,887 shares of the stock traded hands, compared to its average volume of 6,041,216. The business has a fifty day moving average price of $4.29 and a two-hundred day moving average price of $3.30. The firm has a market capitalization of $1.03 billion, a PE ratio of -19.67 and a beta of 2.28. MannKind has a 52 week low of $0.99 and a 52 week high of $6.25.
Several large investors have recently modified their holdings of the company. BlackRock Inc. grew its holdings in shares of MannKind by 1.8% in the 4th quarter. BlackRock Inc. now owns 17,975,840 shares of the biopharmaceutical company’s stock worth $56,264,000 after purchasing an additional 319,869 shares during the last quarter. Avoro Capital Advisors LLC bought a new stake in MannKind during the fourth quarter worth about $10,955,000. Charles Schwab Investment Management Inc. grew its stake in MannKind by 2.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,498,731 shares of the biopharmaceutical company’s stock worth $4,692,000 after buying an additional 29,650 shares during the last quarter. Nuveen Asset Management LLC increased its holdings in shares of MannKind by 62.3% during the fourth quarter. Nuveen Asset Management LLC now owns 1,275,900 shares of the biopharmaceutical company’s stock worth $3,993,000 after buying an additional 489,627 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of MannKind by 4.2% in the fourth quarter. Bank of New York Mellon Corp now owns 687,357 shares of the biopharmaceutical company’s stock valued at $2,151,000 after acquiring an additional 27,450 shares during the last quarter. Institutional investors own 29.60% of the company’s stock.
MannKind Company Profile
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.